Physician profile
Roseann E Brady
NPI 1477604106
$2,933.14
in general payments reported to CMS, 2019-2025
28 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $339 · 2021: $730 · 2022: $560 · 2023: $236 · 2024: $406 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $498.18 | 2020-2025 | Mounjaro, Zepbound, Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.48 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $242.81 | 2020-2021 | |
| Novo Nordisk INC | $227.34 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $140.37 | 2019-2022 | |
| Relievant Medsystems, INC. | $132.62 | 2021 | |
| Pfizer INC. | $131.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $126.92 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.64 | 2019-2022 | |
| Vertiflex, INC. | $109.87 | 2019 | |
| Abbvie INC. | $103.98 | 2021-2022 | |
| Esperion Therapeutics, INC. | $94.67 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $59.53 | 2020-2021 | |
| Ibsa Pharma INC. | $56.80 | 2022-2023 | Tirosint, Licart |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $50.45 | 2022-2023 | Adlarity |
| Dexcom, INC. | $47.16 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $46.82 | 2021-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $41.15 | 2020 | |
| Sunovion Pharmaceuticals INC. | $38.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.64 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $36.83 | 2019 | |
| Philips North America LLC | $34.58 | 2019-2022 | |
| Watermark Medical, INC. | $28.98 | 2022 | |
| Edwards Lifesciences Corporation | $21.94 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Exact Sciences Corporation | $14.61 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $12.72 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roseann Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.